Fairmont Banff Springs Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2010



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

HIV Vaccines (X5)


Organizer(s) Wayne C. Koff, Lynn Morris and Marcus Altfeld
March 21—26, 2010
Fairmont Banff Springs • Banff, Alberta Canada
Abstract Deadline: Nov 19, 2009
Late Abstract Deadline: Dec 23, 2009
Scholarship Deadline: Nov 19, 2009
Early Registration Deadline: Jan 21, 2010

Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation

Joint Meeting: Viral Immunity (X6)

Summary of Meeting:
Traditionally, the Keystone Joint HIV Symposia have integrated vaccines and pathogenesis to comprehensively cover the field—from HIV’s fundamental biology to its interaction with the human immune system and how to design a vaccine—and these Joint Symposia have been convened every year. Since an HIV vaccine is proving to be a particularly recalcitrant problem, a novel approach with this year's experimental format, that facilitates a wider cross-fertilization of ideas would be very valuable and would be welcomed by the broader HIV vaccine research community. To that end, the major development proposed for the 2010 Keystone HIV Vaccine Symposium is to foster innovative ideas and new collaborations with immunology and vaccinology as it pertains to other viral diseases. Specifically, we propose that a new Joint Symposium of HIV Vaccines in conjunction with Viral Immunity be convened. This Joint Symposium would retain the valuable format that includes joint and separate sessions covering general and specific principles.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, MARCH 21

15:00—19:30
Registration

Van Horne Foyer
18:15—19:15
Refreshments

Van Horne Foyer
19:15—19:30
Orientation for New Attendees and New Investigators (Joint)
Keystone Symposia's Chief Scientific Officer, Dr. Andy Robertson, to lead discussion in a "What to Expect during your Attendance" for interested delegates.

Van Horne Ballroom A-B
19:30—21:30
Keynote Session (Joint)
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom A-B
Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard, USA
Durable Control of HIV Infection: Implications for Vaccine Design

Peter C. Doherty, University of Melbourne, Australia
Anti-Viral Immunity: Lessons from Influenza Virus


MONDAY, MARCH 22

06:30—08:00
Breakfast

Mezzanine 2
08:00—11:15
Adaptive Immunity/T- and B-Cell Responses
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom A-B
* Marcus Altfeld, Heinrich-Pette-Institute, Germany

Kim J. Hasenkrug, NIAID, National Institutes of Health, USA
T Cell and B Cell Memory in Protection against Mouse Retrovirus Infection

Richard A. Koup, NIAID, National Institutes of Health, USA
Adaptive Immunity to HIV

Hendrik Streeck, Military HIV Research Program, USA
Short Talk: Increased Control of Viral Replication by HIV-1-Specific CD8+ T Cells Mediated by HIV-Specific CD4+ T Helper Signals

Barbara L. Shacklett, University of California, Davis, USA
Mucosal Immune Responses to HIV Infection

Barton F. Haynes, Duke University Medical Center, USA
B-Cell Immune Responses to Acute HIV Infection

Ann J. Hessell, Oregon Health & Science University, USA
Short Talk: A Non-Fucosylated Variant of the Anti-HIV-1 MAb b12 Results in Greatly Increased ADCC and ADCVI and Binds FcgammaRIIIa with Higher Affinity than Wild-Type b12


Following Session is for Viral Immunity (X6)

08:00—11:15
Innate Recognition of Virus Infection
Meeting has ended...abstracts no longer viewable online.

Van Horne C/Shaughnessy
* Herbert (Skip) W. Virgin, Washington University School of Medicine, USA

Ruslan Medzhitov, HHMI/Yale University School of Medicine, USA
Innate Recognition of Endogenous Retroviruses

Nelson Cesar Di Paolo, Emory University, USA
Short Talk: Adenovirus Binding to beta3 Integrins Activates Innate Antiviral Immunity Independently of the Virus DNA Recognition by Intracellular Sensors

Michael Gale, Jr., University of Washington, USA
Regulation of Pathogen Recognition Receptor Signaling and Innate Immunity by Hepatitis C Virus

Thirumala-Devi Kanneganti, St. Jude Children's Research Hospital, USA
NLRs in Innate Immunity to Influenza Virus

Sammy Bedoui, University of Melbourne, Australia
Short Talk: Priming of CD8 T Cell Immunity to Herpes Simplex Virus Type 1 Requires Cognate TLR3 Expression in vivo

Akiko Iwasaki, HHMI/Yale University School of Medicine, USA
Toll-Like Receptors in Viral Immunity

09:30—09:50
Coffee Break

Van Horne Foyer
11:15
On Own for Lunch and Recreation

11:15—13:00
Poster Setup

Mezzanine 2
13:00—22:00
Poster Viewing

Mezzanine 2
13:00—14:30
Hands-on Computer Session on Los Alamos Sequence Database
Maximum attendance: 60. Interested participants may sign up at the meeting on a first-come, first-serve basis.

Ivor Petrak
* Brian T. Foley, Los Alamos National Laboratory, USA

* Bette Tina Marie Korber, Los Alamos National Laboratory, USA

14:30—16:30
Workshop 1: Advances in Vaccine Development: Clinical Trials

Van Horne Ballroom A-B
* M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA

* Nelson L. Michael, Walter Reed Army Institute of Research, USA
RV 144 Update: Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thai Adults

Jill Gilmour, International AIDS Vaccine Initiative, UK
Short Talk: Induction of Viral Inhibition in Clinical HIV Vaccine Trials of Diverse Immunogens

Julia Rood, University of Pennsylvania, USA
Short Talk: HIV-Specific CD8+ T-Cells of Vaccinees Exhibit Per-Cell Cytotoxic Capacity Comparable to Those of Progressors

Erica Andersen-Nissen, Hutchinson Centre Research Institute of South Africa, South Africa
Short Talk: Systemic Innate Immune Responses to a DNA/MVA Candidate HIV Vaccine

William C. Adams, Columbia University, USA
Short Talk: Adenovirus Type-35 Vectors Block Human CD4+ T Cell Activation by CD46 Ligation

Ruth M. Ruprecht, Texas Biomedical Research Institute, USA
Short Talk: Prevention of Systemic Infection by a Multigenic Recombinant Protein Vaccine after Heterologous R5 Clade C SHIV Challenge: Correlates of Protection

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Control of HIV Infection
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom A-B
* Andrew J. McMichael, Oxford University, UK
Vaccine Design: Lessons from Acute HIV-1 Infection

Mark Brockman, Simon Fraser University, Canada
Short Talk: Reduced Replication Capacity of Recombinant Viruses Encoding Acute/Early HIV-1 Gag-Protease Sequences from Individuals Expressing Protective HLA Class I Alleles

Robert Paul Johnson, Harvard Medical School, New England Primate Research Center, USA
Lessons Learned from Live Attenuated SIV

Guido Silvestri, Emory University School of Medicine, USA
Nonpathogenic Natural SIV Infections


Following Session is for Viral Immunity (X6)

17:00—19:00
Innate Immunity to Viruses
Meeting has ended...abstracts no longer viewable online.

Van Horne C/Shaughnessy
* Akiko Iwasaki, HHMI/Yale University School of Medicine, USA

Herbert (Skip) W. Virgin, Washington University School of Medicine, USA
'Virus-Host Susceptibility Gene' Interactions Control Chronic Inflammatory Disease

Doris Wilflingseder, Innsbruck Medical University, Austria
Short Talk: Complement as an Endogenous Adjuvant for Dendritic Cell-Mediated Induction of Retrovirus-Specific CTLs

Ofer Mandelboim, Hebrew University, Israel
Cellular and Viral microRNAs Controlling Immune Response to Stress

Wayne M. Yokoyama, Washington University School of Medicine, USA
NK Cells, CTLs, and Virus Infection: Missing-Self in Action?

19:00—20:00
Social Hour with Lite Bites

Mezzanine 2
19:30—22:00
Poster Session 1

Mezzanine 2

TUESDAY, MARCH 23

06:30—08:00
Breakfast

Mezzanine 2
08:00—11:45
Neutralizing Antibody
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom A-B
Eric Hunter, Emory University, USA
and

Cynthia A. Derdeyn, Emory University, USA
Recently Transmitted HIV and the Early Neutralizing Antibody Response

Peter D. Kwong, NIAID, National Institutes of Health, USA
Antibody VRC01: To Be or Not To Be Like CD4

Sriram Subramaniam, National Institutes of Health, USA
Molecular Architecture of Trimeric SIV and HIV-1 Envelope Glycoproteins

Quentin J. Sattentau, Sir William Dunn School of Pathology, UK
Antigen and Adjuvant Design for Antibody-Based HIV-1 Vaccination

* Lynn Morris, National Institute for Communicable Diseases, South Africa
How Does Neutralization Breadth Develop in HIV Infection

Joseph Joyce, Merck & Co., Inc., USA
Short Talk: Vaccination with Peptide Mimetics of the gp41 Pre-Hairpin Fusion Intermediate Yields Neutralizing Antisera Against HIV-1 Isolates


Following Session is for Viral Immunity (X6)

08:00—11:15
T-Cell Immunity to Viruses
Meeting has ended...abstracts no longer viewable online.

Van Horne C/Shaughnessy
* Jack R. Bennink, NIAID, National Institutes of Health, USA

Nicole L. La Gruta, University of Melbourne, Australia
Dissection of CTL Immunodominance Determinants Following Viral Infection

Guna Karupiah, John Curtin School of Medical Research, Australian National University, Australia
Short Talk: The Biological Significance of Proliferation-Independent Expansion of Antigen-Specific CD8+ T Cells through Receptor Sharing

Andrea Lynn Cox, Johns Hopkins University, USA
Analysis of T Cells Chasing Hepatitis C Virus Escape Variants

Ann B. Hill, Oregon Health & Science University, USA
CD8+ T Cells and Cytomegalovirus: A Dangerous Obsession?

Linda S. Cauley, University of Connecticut Health Center, USA
Short Talk: Cause and Effects of Prolonged Lymph Node Hypertrophy after Influenza Infection

J. Lindsay Whitton, The Scripps Research Institute, USA
CD8+ T Cell Responses To Infection: A Tale Of Two Viruses

09:50—10:10
Coffee Break

Van Horne Foyer
11:45
On Own for Lunch and Recreation

11:45—13:00
Poster Setup

Mezzanine 2
13:00—22:00
Poster Viewing

Mezzanine 2
13:00—14:30
Hands-on Computer Session on Los Alamos Sequence Database
Maximum attendance: 60. Interested participants may sign up at the meeting on a first-come, first-serve basis.

Ivor Petrak
* Brian T. Foley, Los Alamos National Laboratory, USA

* Bette Tina Marie Korber, Los Alamos National Laboratory, USA


Following Session is for Viral Immunity (X6)

14:30—16:30
Workshop 1: ANTI-VIRAL CD8 T CELL RESPONSES

Van Horne Ballroom C
* Tania H. Watts, University of Toronto, Canada

* David C. Tscharke, Australian National University, Australia


Following Session is for Viral Immunity (X6)

14:30—15:30
Workshop 1A: CD8 T Cell Memory

Van Horne Ballroom C
Jeffrey C. Nolz, University of Iowa, USA
Multiple Antigen Encounters Decrease the Protective Capacity of the Ensuing Memory CD8 T Cell Population Against Chronic LCMV Infection

John Rutigliano, St. Jude Children's Research Hospital, USA
Development and Differentiation of Memory CD8+ T Cells in Influenza Infection

Hélène Decaluwe, CHU Sainte-Justine, Canada
Gamma c Deficiency Precludes CD8+ T Cell Memory Despite Formation of Potent Anti-Viral T Cell Effectors

Amol Suryawanshi, Georgia Regents University, USA
Galectin-9/TIM-3 Interaction Regulates Virus-Specific Primary and Memory CD8+T Cell Response


Following Session is for Viral Immunity (X6)

15:30—16:30
Workshop 1B: Virus Specific CD8 T Cells

Van Horne Ballroom C
Alice E. Denton, University of Melbourne, Australia
Epigenetic Regulation in CD8+ T Cell Differentiation

Bailey E. Freeman, Oregon Health & Science University, USA
Cytokine-Mediated Regulation of CD8+ T Cell Responses during LCMV Infection

Lila Ann Farrington, University of California, San Francisco, USA
Virus-Infected Cells are Extremely Resistant to CTL-Mediated Killing

Silvia Ariotti, Netherlands Cancer Institute, Netherlands
In vivo Imaging of Target Localization by Virus-Specific Cytotoxic T Lymphocytes

14:30—16:30
Workshop 2: Novel Vector and Adjuvant Development

Van Horne Ballroom A-B
* Gerald H. Voss, GlaxoSmithKline Biologicals, Belgium

John K. Rose, Yale University School of Medicine, USA
Short Talk: Strong Protection Against SIVsmE660 Mucosal Challenge Conferred by a Novel, Heterologous, Prime-Boost Vaccine Regimen

Mauricio A. Martins, University of Miami, USA
Short Talk: Recombinant Yellow Fever Vaccine Virus 17D Expressing SIVmac239 Gag Induces SIV-Specific CD8+ T Cell Responses in Rhesus Macaques

* Nancy L. Haigwood, Oregon Health & Science University, USA
Short Talk: Novel VLPs Rapidly Induce High Titer Neutralizing Antibodies when Combined with DNA Vaccines in Rabbits

Adrian B. McDermott, National Institutes of Health, USA
Short Talk: Control of Pathogenic SIVmac239 Following Electroporated DNA + IL-12 Prime and Adenovirus 5 Boost in a Study Designed to Compare Priming Strategies in the NHP Model

Magdalini Moutaftsi, Infectious Disease Research Institute, USA
Short Talk: Glucopyranosyl Lipid A (GLA), a Synthetic TLR4 Vaccine Adjuvant, Induces Potent Th1-Promoting Immune Responses

Anna Bershteyn, Massachusetts Institute of Technology, USA
Short Talk: Versatile Lipid-Based Vaccine Carriers Elicit CTL and Antibody Responses to Surface-Conjugated or Encapsulated Antigen

Ben Berkhout, University of Amsterdam, Academic Medical Center, Netherlands
Short Talk: Live Attenuated SIV: Characterising the Role of Vaccine Persistence in Protection

Tomas Hanke, University of Oxford, UK
Short Talk: Long Peptides Induce Polyfunctional Macaque T Cells Against Conserved Regions of HIV-1 with Superior Breadth to Single-Gene Vaccines

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Innate Immunity
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom A-B
* Bali Pulendran, Emory University, USA

Marcus Altfeld, Heinrich-Pette-Institute, Germany
Natural Killer Cells in HIV-1 Infection

Silke Paust, Baylor College of Medicine, USA
Short Talk: Critical Role for CXCR6 in NK Cell Mediated Adaptive Immunity to Viruses

Mariapia A. Degli-Esposti, LEI, University of Western Australia, Australia
NK/DC Crosstalk and Regulation of Adaptive Immunity

Veronica Anna Sofia Tjomsland, University of Linköping, Sweden
Short Talk: Receptors and Pathways Utilized by Dendritic Cells for Antigen Presentation of Free and Complement Opsonized HIV

Jay A. Berzofsky, NCI, National Institutes of Health, USA
Short Talk: Innate and Adaptive Immune Correlates of Vaccine-Induced Control of Mucosal Transmission of SIV in Macaques


Following Session is for Viral Immunity (X6)

17:00—19:00
Routes of Antigen Presentation
Meeting has ended...abstracts no longer viewable online.

Van Horne C/Shaughnessy
* Nicole L. La Gruta, University of Melbourne, Australia

Laurence C. Eisenlohr, Children's Hospital of Philadelphia and University of Pennsylvania, USA
A Proteasome- and TAP-Dependent MHC Class II-Restricted Presentation Pathway that Stimulates a Substantial Portion of the Antiviral CD4+ T Cell Response: Part 2

Margarita Del Val, Centro de Biología Molecular Severo Ochoa, Spain
Short Talk: Furin-Processed Antigens Targeted to the Secretory Route Elicit Functional TAP1-/- CD8+ T Lymphocytes in vivo

Sylvie Le Gall, Massachusetts General Hospital, Harvard Medical School, USA
Deciphering HIV Epitope Production: Implications for Immunogen Design

William R. Heath, University of Melbourne, Australia
Viral Antigen Presentation to Naïve and Memory CD8+ T Cells

19:00—20:00
Social Hour with Lite Bites

Mezzanine 2
19:30—22:00
Poster Session 2

Mezzanine 2

WEDNESDAY, MARCH 24

06:30—08:00
Breakfast

Mezzanine 2
08:00—11:15
Vaccines: Immunologic Mechanisms of Action (Joint)
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom A-B
* Kim J. Hasenkrug, NIAID, National Institutes of Health, USA

Bali Pulendran, Emory University, USA
Lessons from Yellow Fever Vaccine

Ian Frazer, TRI, Australia
Lessons from the Human Papillomavirus Vaccines

Shane Crotty, La Jolla Institute for Allergy and Immunology, USA
Lessons from the Smallpox Vaccine: Follicular Helper CD4+ T Cell (Tfh) Differentiation and Neutralizing Antibodies

Mark Stephen de Souza, AFRIMS, Thailand
Short Talk: Immunogenicity of the Thai Phase III (RV144) HIV Vaccine Regimen

Monica Vaccari, NCI, National Institutes of Health, USA
Short Talk: HIV/SIV Vaccine Efficacy Dependent on the Dose of SIVmac251 Challenge Exposure in Macaques

M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Lessons from the STEP Trial and the Current Clinical Pipeline

09:50—10:10
Coffee Break

Van Horne Foyer
11:15
On Own for Lunch and Recreation

11:15—13:00
Poster Setup

Mezzanine 2
13:00—22:00
Poster Viewing

Mezzanine 2
16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Imaging of the Antiviral Immune Response (Joint)
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom A-B
* Jonathan W. Yewdell, NIAID, National Institutes of Health, USA

Heather D. Hickman, NIAID, National Institutes of Health, USA
Intravital Imaging of the CD8+ T Cell Response to Virus

Matteo Iannacone, Vita-Salute San Raffaele University, Italy
Short Talk: Lymph Node Subcapsular Sinus Macrophages Confer Resistance to CNS Invasion Upon Peripheral Infection With a Neurotropic Virus

Ashley T. Haase, University of Minnesota, USA
In Vivo Imaging of the Cellular Immune Response to Viral Infections

Ronald N. Germain, NIAID, National Institutes of Health, USA
Intravital Imaging of Adaptive Immune Effector Activity

19:00—20:00
Social Hour with Lite Bites

Mezzanine 2
19:30—22:00
Poster Session 3

Mezzanine 2

THURSDAY, MARCH 25

06:30—08:00
Breakfast

Mezzanine 2
07:00—12:00
Poster Setup

Mezzanine 2
07:00—12:00
Poster Viewing

Mezzanine 2
08:00—11:15
Novel Vaccine Approaches
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom A-B
Gerald H. Voss, GlaxoSmithKline Biologicals, Belgium
AS01, an Adjuvant System Potentiating Vaccines against Complex Pathogens

Bette Tina Marie Korber, Los Alamos National Laboratory, USA
Vaccine Antigen Designs to Address HIV Variability

Dan H. Barouch, Harvard Medical School/Beth Israel Deaconess Medical Center, USA
Short Talk: Heterologous Rare Serotype Adenovirus Vectors for HIV-1 +

* Louis J. Picker, Oregon Health & Science University, USA
Cytomegalovirus Vectors

R. Brad Jones, Ragon Institute of MGH, MIT and Harvard, USA
Short Talk: Comprehensive Elimination of Globally Diverse HIV Primary Isolate Infections by HERV-K-Specific CD8+ T Cells

Wayne C. Koff, International AIDS Vaccine Initiative, USA
Future Directions in AIDS Vaccine Development


Following Session is for Viral Immunity (X6)

08:00—11:15
Immunity to Chronic and Persistent Viral Infections
Meeting has ended...abstracts no longer viewable online.

Van Horne C/Shaughnessy
* Peter C. Doherty, University of Melbourne, Australia

Marcia A. Blackman, Trudeau Institute, USA
Establishment, Maintenance and Immune Control of gamma-Herpesvirus Latency

Ilhem Messaoudi, Oregon Health & Science University, USA
Short Talk: Elucidating the Role of T Cell Immunity in the Control of VZV Replication using a Novel Nonhuman Primate Model

Emmanuel J. Wiertz, University Medical Center Utrecht, Netherlands
Herpesvirus Interference with T-Cell Immunity

Elina I. Zuniga, University of California, San Diego, USA
Short Talk: Sustained-Cell-Intrinsic Transforming Growth Factor-beta Signaling Mediates Virus-Specific CD8+ T Cell Deletion and Viral Persistence in vivo

Barbara Rehermann, NIDDK, National Institutes of Health, USA
Immunity to Hepatitis C Virus

Francis V. Chisari, The Scripps Research Institute, USA
Induction and Evasion of the Innate Host Response to HCV

09:30—09:50
Coffee Break

Van Horne Foyer
11:15—13:00
Lunch

Mezzanine 2
12:00—14:30
Poster Session 4

Mezzanine 2

Following Session is for Viral Immunity (X6)

14:30—16:30
Workshop 2: Anti-Viral T and B-Cells

Shaughnessy
* Cornelia C. Bergmann, Cleveland Clinic Foundation, USA

* Kevin L. Legge, University of Iowa Carver College of Medicine, USA


Following Session is for Viral Immunity (X6)

14:30—15:30
Workshop 2A: Anti-Viral CD4 and CD8 T Cell Responses

Shaughnessy
Anna Haas, Swiss Federal Institute of Technology, Switzerland
HIV-1 Replication Activates CD4+ T Cells with Specificities for Persistent Herpes Viruses

Mickael J. Ploquin, Institut Pasteur, France
B Cells Shape the T Helper Response to Retroviral Infection

David E. Verhoeven, Iowa State University, USA
Memory CD4+ T-Cells Mediate Enhanced Immunopathology during Influenza Infection

Jennifer Bomberger, University of Pittsburgh School of Medicine, USA
The Pseudomonas aeruginosa Toxin Cif Reduces MHC Class I Antigen Presentation and Viral Immunity

14:30—16:30
Workshop 3: HIV Pathogenesis to Inform Vaccine Design

Van Horne Ballroom A-B
* David I. Watkins, University of Miami, Miller School of Medicine, USA

* Barbara L. Shacklett, University of California, Davis, USA

Srinika R. F. Ranasinghe, Ragon Institute of MGH, MIT and Harvard, USA
Short Talk: The Antiviral Efficacy of HIV-Specific CD8+ T-Cells to a Conserved Epitope is Heavily Dependent on the Infecting HIV-1 Isolate

Anne-Sophie M. Dugast, Ragon Institute of MGH, MIT and Harvard, USA
Short Talk: Significant Impairment in Innate Immune Cells Recruitment by Chronic Untreated Antibodies to Mediate ADCC

Matthew R. Reynolds, University of Wisconsin-Madison, USA
Short Talk: Macaques Vaccinated with SIVmac239deltanef Delay Acquisition and Control Replication after Repeated Low Dose Heterologous SIV Challenge

Todd M. Allen, Ragon Institute of MGH, MIT and Harvard, USA
Short Talk: Ultra-Deep Sequencing During Acute HIV Infection Reveals the Earliest Adaptive Changes to Host Selection Pressures

Qingsheng Li, University of Nebraska Center for Virology, USA
Short Talk: Maturation of Virus-specific Antibodies in Cervicovaginal Tissues in SIVmac239deltanef-vaccinated Macaques

Suzanne English, University of Oxford, UK
Short Talk: Sexual Transmission of Highly-Distinct HIV-1 Variants from a Single Donor to Two Recipients on the Same Night: Divergent Immune-Recognition and Clinical Outcomes

Suresh Pallikkuth, University of Miami, USA
Short Talk: Recombinant IL-21 Induces Cytotoxic Molecule Granzyme B in Lymph Nodes of Chronic SIV Infected Rhesus Macaques

Adam D. Burgener, Public Health Agency of Canada, Canada
Short Talk: HIV-1-Resistant Sex Workers Overexpress Novel Antiproteases and Antiviral Factors in their Cervical Mucosa. Protective Milieu Against HIV-1 Infection?


Following Session is for Viral Immunity (X6)

15:30—16:30
Workshop 2B: B Cell Responses to Viruses

Shaughnessy
Matthew R. Vogt, Washington University School of Medicine, USA
Non-Neutralizing Antibodies Protect against Lethal West Nile Virus Infection via Fc-gamma Receptor and Complement–dependent Mechanisms

Santiago F. Gonzalez, Immune Disease Institute, USA
Capture of Influenza by Medullary Dendritic Cells is Essential for Humoral Immunity in Draining Lymph Nodes

Denise A. Kaminski, University of Rochester, USA
Antiviral Activity of Influenza Nucleoprotein-Specific Antibodies

Luis J. Sigal, Fox Chase Cancer Center, USA
Not just Neutralizing Abs: Prevention and Cure of a Viral Disease by Antibodies that Block the Biological Function of a Virulence Factor


Following Session is for Viral Immunity (X6)

14:30—16:30
Workshop 3: Innate Immunity to Virus Infection

Van Horne Ballroom C
* Adolfo García-Sastre, Mount Sinai School of Medicine, USA

* Hans-Gustaf Ljunggren, Karolinska Institutet, Sweden


Following Session is for Viral Immunity (X6)

14:30—15:30
Workshop 3A: Immunity to Viruses

Van Horne Ballroom C
Maulik Patel, Vanderbilt University, USA
Evolution as a Guide to Molecular Mechanisms of Pathogen Resistance

Helene Minyi Liu, National Taiwan University, Taiwan
RIG-I Membrane-Association Controls Innate Antiviral Immunity

Alina Baum, Mount Sinai School of Medicine, USA
Characterization of Endogenous RIG-I Substrates from Virus Infected Cells

Irving C. Allen, Virginia Tech, USA
NLRX1 is a Regulator of the Innate Immune Response to Influenza A Virus Infection


Following Session is for Viral Immunity (X6)

15:30—16:30
Workshop 3B: Innate Cellular Responses to Viruses

Van Horne Ballroom C
Karyl Kopaskie, University of Chicago, USA
Evasion of the Immune Response by Retroviriuses

Mark T. Orr, Infectious Disease Research Institute, USA
“Unlicensed” NK Cells Dominate the Response to Cytomegalovirus Infection

Stephen A. McCartney, Washington University School of Medicine, USA
Distinct Functions of MDA5 and TLR3 in poly-I:C-mediated Activation of Murine NK Cells

Stephanie Jost, Ragon Institute of MGH, MIT and Harvard, USA
Modulation of 2B4 and NKp46 Expression at the Surface of NK Cells in Response to Influenza Virus

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Antigenic Variation (Joint)
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom A-B
* Wayne C. Koff, International AIDS Vaccine Initiative, USA

David I. Watkins, University of Miami, Miller School of Medicine, USA
The Effect of Vaccine-Induced SIV-Specific Immune Response on Viral Acquisition and Replication

Arnaud Moris, INSERM - CNRS - UPMC - Hôpital Pitié-Salpêtrière, France
Short Talk: The Antiviral Factor APOBEC3G Improves CTL Recognition of HIV-Infected T Cells: Linking Intrinsic and Adaptive Immune Responses

Dennis R. Burton, The Scripps Research Institute, USA
HIV Env and Approaches to Neutralizing Abs

Jonathan W. Yewdell, NIAID, National Institutes of Health, USA
Still Drifting: Mechanisms of Influenza A Virus Hemagglutinin Immune Escape

19:00—20:00
Social Hour with Lite Bites

Mezzanine 2
20:00—23:00
Entertainment

Mezzanine 2

FRIDAY, MARCH 26

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI087261-01A1




We gratefully acknowledge additional support for this conference from:

Bill & Melinda Gates Foundation
National Institute of Allergy and Infectious Diseases
Office of AIDS Research, NIH
National Institute of Allergy and Infectious Diseases

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



GlaxoSmithKline Biologicals


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676